Published Year:2020
Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Ap
The global market for infectious disease rapid diagnostics is predicted to grow at a CAGR of...
A quick peek into the report
Report Description
Market Report Coverage -Â Infectious Disease Biomarker Testing
Forecast Period: 2020-2030
CAGR: 14.48%
Key Questions Answered in this Report:
What is a biomarker and what is the importance of biomarker testing?
Market Overview
Owing to the recent COVID-19 outbreak, the infectious disease biomarker testing market is expected to grow dynamically
Table of Contents
1.1 Inclusion and Exclusion
2.1 Overview: Report Scope
2.2 Segmentation of the Global Infectious Disease Biomarker Testing Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in the Report
2.5 Base Year and Forecast Period
3.1 Overview: Report Methodology
4.1 Introduction
4.2 Importance of Biomarkers
4.3 Types of Biomarkers Used in Clinical Applications
4.3.1 Biomarkers for Risk Prediction:
4.3.2 Biomarker for Diseases:
4.4 Infectious Disease Biomarker Testing Approach
4.5 Point-of-Care (POC) Testing for Infectious Diseases
4.6 Infectious Disease Biomarker Tests Available in the Market
4.7 Global Footprint
5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Increasing Burden of Pervasively Growing Rate of Infectious Diseases
5.3.2 Advancements in Molecular Techniques and Increased Investment on Biomarker Testing by NGS Players
5.3.3 Boosting Research and Increasing Funding Activities for Clinical Biomarkers
5.3.4 Booming Clinical Diagnostic Test Market and Rising Uptake of Biomarker Tests Among Healthcare Professionals
5.4 Market Restraints
5.4.1 Poorly Suited Reimbursement Policies
5.4.2 High Capital Investments and Lack of Intricate Testing Centers
5.4.3 Uncertain Regulatory Framework Delaying Tests Approval
5.5 Market Opportunities
5.5.1 Untapped Potential of Emerging Nations Creating Vast Opportunities
5.5.2 Rapid Technological Advancements and Inclination Toward Automation
5.5.3 Widespread Emergence of CROs Specializing on Infectious Diseases
6.1 Industry Trends
6.2 Effect of Pandemics and Epidemics on the Infectious Disease Biomarker Testing Market
6.3 Effect of COVID-19 on the Global Healthcare Industry
6.3.1 Negative Impact on Non-Communicable Disease Sectors
6.3.2 Positive Impact on Infectious Disease Diagnostic Sector
6.4 COVID-19 Impact on Global Infectious Disease Biomarker Testing Market
6.4.1 Situation Analysis: Pre-COVID-19 Outbreak, During COVID-19 Outbreak and Post COVID-19 Outbreak
6.4.2 Impact on Respiratory Infection Segment
6.5 Challenges Associated with Infectious Disease Research
7.1 Overview
7.2 Key Developments and Strategies
7.2.1 Product Approval
7.2.2 New Offerings
7.2.3 Partnerships and Alliances
7.2.4 M&A Activities
7.2.5 Others
7.3 Market Share Analysis
7.4 Growth Share Analysis (Opportunity Mapping)
7.4.1 By Application
7.4.2 By Technology
8.1 Overview
8.2 Assays
8.2.1 Overview
8.2.2 Market Scenario
8.3 Platforms
8.3.1 Overview
8.3.2 Market Scenario
9.1 Overview
9.2 Respiratory Infection
9.2.1 Overview
9.2.2 Common Pathogens Associated with Respiratory Infection
9.2.3 Market Scenario
9.3 Sexually Transmitted Infection
9.3.1 Overview
9.3.2 Common Pathogens Associated with Sexually Transmitted Infection
9.3.3 Market Scenario
9.4 Bloodstream and Hospital-Acquired Infection
9.4.1 Overview
9.4.2 Common Pathogens Associated with Bloodstream and Hospital Acquired Infections
9.4.3 Market Scenario
9.5 Urinary Tract Infection
9.5.1 Overview
9.5.2 Common Causes of Urinary tract infection (UTI)
9.5.3 Market Scenario
9.6 Gastro-Intestinal Infection
9.6.1 Overview
9.6.2 Common Causes of Gastro-Intestinal (GI) Infection
9.6.3 Market Scenario
9.7 Central Nervous System Infection
9.7.1 Overview
9.7.2 Common Causes of CNS Infection
9.7.3 Market Scenario
9.8 Others
10.1 Overview
10.2 PCR
10.2.1 Overview
10.2.2 Market Scenario
10.3 NGS
10.3.1 Overview
10.3.2 Market Scenario
10.4 ELISA or EIA
10.4.1 Overview
10.4.2 Market Scenario
10.5 IHC
10.5.1 Overview
10.5.2 Market Scenario
10.6 ISH
10.6.1 Overview
10.6.2 Market Scenario
10.7 Others
11.1 Overview
11.2 Virus
11.2.1 Overview
11.2.2 Examples of Common Viral Infections
11.2.3 Market Scenario
11.2.4 Market Segmentation by Different Viral Infection
11.2.4.1 Influenza
11.2.4.2 HIV-AIDS
11.2.4.3 Hepatitis
11.2.4.4 HPV
11.2.4.5 Other Viruses
11.3 Bacteria
11.3.1 Overview
11.3.2 Examples of Common Viral Infections
11.3.3 Market Scenario
11.3.4 Market Segmentation by Different Bacterial Infection
11.3.4.1 Hospital-Acquired Infection
11.3.4.2 Tuberculosis
11.3.4.3 CT/NG
11.3.4.4 Other Bacteria
11.4 Others
12.1 Overview
12.2 Hospitals and Clinics
12.3 Diagnostic Centers
12.4 Research Laboratories
12.5 Other End Users
13.1 Overview
13.2 North America
13.2.1 Overview
13.2.2 U.S.
13.2.3 Canada
13.3 Europe
13.3.1 Overview
13.3.2 Germany
13.3.3 U.K.
13.3.4 France
13.3.5 Italy
13.3.6 Spain
13.3.7 Switzerland
13.3.8 Netherlands
13.3.9 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 Overview
13.4.2 China
13.4.3 Japan
13.4.4 India
13.4.5 Australia
13.4.6 Singapore
13.4.7 South Korea
13.4.8 Rest-of-Asia-Pacific
13.5 Rest-of-the-World
13.5.1 Overview
13.5.2 Latin America
13.5.3 Middle East and Africa
14.1 Overview
14.2 Abacus Diagnostica Oy
14.2.1 Company Overview
14.2.2 Role of Abacus Diagnostica Oy in the Global Infectious Disease Biomarker Testing Market
14.2.3 SWOT Analysis
14.3 Abbott Laboratories
14.3.1 Company Overview
14.3.2 Role of Abbott Laboratories in the Global Infectious Disease Biomarker Testing Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 Agilent Technologies, Inc.
14.4.1 Company Overview
14.4.2 Role of Agilent Technologies, Inc. in the Global Infectious Disease Biomarker Testing Market
14.4.3 Financials
14.4.4 Key Insights About Financial Health of the Company
14.4.5 SWOT Analysis
14.5 ALPCO
14.5.1 Company Overview
14.5.2 Role of ALPCO in the Global Infectious Disease Biomarker Testing Market
14.5.3 SWOT Analysis
14.6 Becton, Dickinson and Company
14.6.1 Company Overview
14.6.2 Role of Becton, Dickinson and Company in the Global Infectious Disease Biomarker Testing Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 bioMérieux SA
14.7.1 Company Overview
14.7.2 Role of bioMérieux SA in the Global Infectious Disease Biomarker Testing Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 Bio-Rad Laboratories, Inc.
14.8.1 Company Overview
14.8.2 Role of Bio-Rad Laboratories, Inc. in the Global Infectious Disease Biomarker Testing Market
14.8.3 Financials
14.8.4 Key Insights About Financial Health of the Company
14.8.5 SWOT Analysis
14.9 Danaher Corporation
14.9.1 Company Overview
14.9.2 Role of Danaher Corporation in the Global Infectious Disease Biomarker Testing Market
14.9.3 Financials
14.9.4 Key Insights About Financial Health of the Company
14.9.5 SWOT Analysis
14.10 F. Hoffmann-La Roche Ltd
14.10.1 Company Overview
14.10.2 Role of F. Hoffmann-La Roche Ltd in the Global Infectious Disease Biomarker Testing Market
14.10.3 Financials
14.10.4 Key Insights About Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Hologic, Inc.
14.11.1 Company Overview
14.11.2 Role of Hologic, Inc. in the Global Infectious Disease Biomarker Testing Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 PerkinElmer, Inc.
14.12.1 Company Overview
14.12.2 Role of PerkinElmer, Inc. in the Global Infectious Disease Biomarker Testing Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 QIAGEN N.V.
14.13.1 Company Overview
14.13.2 Role of QIAGEN N.V. in the Global Infectious Disease Biomarker Testing Market
14.13.3 Financials
14.13.4 Key Insights About Financial Health of the Company
14.13.5 SWOT Analysis
14.14 Quest Diagnostics Incorporated
14.14.1 Company Overview
14.14.2 Role of Quest Diagnostics Incorporated in the Global Infectious Disease Biomarker Testing Market
14.14.3 Financials
14.14.4 SWOT Analysis
14.15 Siemens Healthineers AG
14.15.1 Company Overview
14.15.2 Role of Siemens Healthineers AG in the Global Infectious Disease Biomarker Testing Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Thermo Fisher Scientific, Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific, Inc. in the Global Infectious Disease Biomarker Testing Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
Table 1: Prominent Outbreaks, Epidemics, and Pandemics of Recent Decades
Table 2: Leading Segments of the Global Infectious Disease Biomarker Testing Market, 2019 and 2030
Table 4.1: Advantages and Disadvantages of Biomarkers in Diagnostic Tests
Table 4.2: Key Commercialized Products Offered by Major Market Players
Table 5.1: Impact Analysis of Market Drivers
Table 5.2: Impact Analysis of Market Restraints
Table 5.3: Number of Deaths by Cause, 2017
Table 6.1: Impact of COVID-19 on Different Countries
Table 6.2: Tests Conducted per new Confirmed Case of COVID-19
Table 6.3: COVID-19 Related Product Offering by Major Players
Table 8.1: Key Biomarker Testing Assays Offered by Major Market Players
Table 8.2: Key Biomarker Testing Assays Offered by Major Market Players
Table 9.1: Pathogens Responsible for Different Respiratory Infections
Table 9.2: Key Biomarker Testing Products for Respiratory Infection Offered by Major Market Players
Table 9.3: Key Biomarker Testing Products for Sexually Transmitted Infection Offered by Major Market Players
Table 9.4: Key Biomarker Testing Products for Bloodstream and Hospital Acquired Infection Offered by Major Market Players
Table 9.5: Key Biomarker Testing Products for Urinary Tract Infection Offered by Major Market Players
Table 9.6: Key Biomarker Testing Products for Gastro-Intestinal Infection Offered by Major Market Players
Table 9.7: Key Biomarker Testing Products for CNS Infection Offered by Major Market Players
Table 9.8: Key Biomarker Testing Products for other Infections Offered by Major Market Players
Table 10.1: Key PCR-based Biomarker Testing Products Offered by Major Market Players
Table 10.2: Key NGS-based Biomarker Testing Products Offered by Major Market Players
Table 10.3: Key ELISA-based Biomarker Testing Products Offered by Major Market Players
Table 10.4: Key IHC-based Biomarker Testing Products Offered by Major Market Players
Table 11.1: Key Biomarker Testing Products for Viral Infection Offered by Major Market Players
Table 11.2: Key Biomarker Testing Products for Bacterial Infection Offered by Major Market Players
Table 13.1: Projected 2030 Mortality and 10-Year Trends for Selected Infections, by Country Income Group
Figure 1: Global Infectious Disease Biomarker Testing Market (by Region), 2019 and 2030
Figure 2: Key Players of the Global Infectious Disease Biomarker Testing Market
Figure 3: Global Infectious Disease Biomarker Testing Market - Drivers, Challenges, and Opportunities
Figure 4: Impact of COVID-19 on the Growth of Global Infectious Disease Biomarker Testing Market, 2019-2025
Figure 5: Share of Key Developments and Strategies, January 2017-April 2020
Figure 6: Global Infectious Disease Biomarker Testing Market (by Product), 2019-2030
Figure 7: Global Infectious Disease Biomarker Testing Market (by Application), 2019-2030
Figure 8: Global Infectious Disease Biomarker Testing Market (by Technology), 2019-2030
Figure 9: Global Infectious Disease Biomarker Testing Market (by Pathogen), 2019-2030
Figure 10: Global Infectious Disease Biomarker Testing Market (by End User), 2019-2030
Figure 2.1: Global Infectious Disease Biomarker Testing Market Segmentation
Figure 3.1: Global Infectious Disease Biomarker Testing Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 4.1: Global Infectious Disease Biomarker Testing Market, with Y-o-Y, 2019-2030
Figure 6.1: Recent Pandemics/Epidemics
Figure 6.2: Impact of COVID-19 on the Growth of Global Infectious Disease Biomarker Testing Market, 2019-2030
Figure 6.3: Global Infectious Disease Biomarker Market Share (by Application), 2019 and 2020
Figure 7.1: Competitive Landscape (January 2017–April 2020)
Figure 7.2: Share of Key Developments and Strategies, January 2017-April 2020
Figure 7.3: Product Approvals (by Company), January 2017 and April 2020
Figure 7.4: New Offerings (by Company), January 2017 and April 2020
Figure 7.5: Partnerships and Alliances (by Company), January 2017 and April 2020
Figure 7.6: M & A Activities (by Company), January 2017 and April 2020
Figure 7.7: Market Share Analysis of Global Infectious Disease Biomarker Testing Market, 2018 and 2019
Figure 7.8: Growth Share Matrix for Global Infectious Disease Biomarker Testing Market (by Application), 2019-2030
Figure 7.9: Growth Share Matrix for Global Infectious Biomarker Testing Market (by Technology), 2019-2030
Figure 8.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Product)
Figure 8.2: Global Infectious Disease Biomarker Testing Market (by Product), 2019-2030
Figure 8.3: General Workflow of a Molecular Diagnostic Kit
Figure 8.4: Global Infectious Disease Biomarker Testing Market for Assay, 2019-2030
Figure 8.5: Global Infectious Disease Biomarker Testing Market for Platforms, 2019-2030
Figure 9.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Application)
Figure 9.2: Global Infectious Disease Biomarker Testing Market (by Application), 2019-2030
Figure 9.3: Global Infectious Disease Biomarker Testing Market for Respiratory Infection, 2019-2030
Figure 9.4: Global Infectious Disease Biomarker Testing Market for Sexually Transmitted Infection, 2019-2030
Figure 9.5: Global Infectious Disease Biomarker Testing Market for Bloodstream and Hospital Acquired Infections, 2019-2030
Figure 9.6: Global Infectious Disease Biomarker Testing Market for Urinary Tract Infections, 2019-2030
Figure 9.7: Global Infectious Disease Biomarker Testing Market for Gastro-Intestinal Infections, 2019-2030
Figure 9.8: Global Infectious Disease Biomarker Testing Market for CNS Infections, 2019-2030
Figure 9.9: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
Figure 10.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Technology)
Figure 10.2: Global Infectious Disease Biomarker Testing Market (by Technology), 2019-2030
Figure 10.3: Global Infectious Disease Biomarker Testing Market for PCR, 2019-2030
Figure 10.4: Global Infectious Disease Biomarker Testing Market for NGS, 2019-2030
Figure 10.5: Global Infectious Disease Biomarker Testing Market for ELISA or EIA, 2019-2030
Figure 10.6: Global Infectious Disease Biomarker Testing Market for IHC, 2019-2030
Figure 10.7: Global Infectious Disease Biomarker Testing Market for ISH, 2019-2030
Figure 10.8: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
Figure 11.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Pathogen)
Figure 11.2: Global Infectious Disease Biomarker Testing Market (by Pathogen), 2019-2030
Figure 11.3: Global Infectious Disease Biomarker Testing Market for Virus, 2019-2030
Figure 11.4: Global Biomarker Testing Market for Virus (by Viral Infection), 2019-2030
Figure 11.5: Global Infectious Disease Biomarker Testing Market for Influenza Virus, 2019-2030
Figure 11.6: Global Infectious Disease Biomarker Testing Market for HIV, 2019-2030
Figure 11.7: Global Infectious Disease Biomarker Testing Market for Hepatitis, 2019-2030
Figure 11.8: Global Infectious Disease Biomarker Testing Market for HIV, 2019-2030
Figure 11.9: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
Figure 11.10: Global Infectious Disease Biomarker Testing Market for Bacteria, 2019-2030
Figure 11.11: Global Biomarker Testing Market for Bacteria (by Bacteria Infection), 2019-2030
Figure 11.12: Global Infectious Disease Biomarker Testing Market for Hospital-Acquired Infection, 2019-2030
Figure 11.13: Global Infectious Disease Biomarker Testing Market for Tuberculosis, 2019-2030
Figure 11.14: Global Infectious Disease Biomarker Testing Market for CT/NG, 2019-2030
Figure 11.15: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
Figure 11.16: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
Figure 12.1: Global Infectious Disease Biomarker Testing Market Segmentation (by End User)
Figure 12.2: Global Infectious Disease Biomarker Testing Market (by End User), 2019-2030
Figure 12.3: Global Infectious Disease Biomarker Testing Market for Hospitals and Clinics, 2019-2030
Figure 12.4: Global Infectious Disease Biomarker Testing Market for Diagnostic Centers, 2019-2030
Figure 12.5: Global Infectious Disease Biomarker Testing Market for Research Laboratories, 2019-2030
Figure 12.6: Global Infectious Disease Biomarker Testing Market for Other End Users, 2019-2030
Figure 13.1: Global Infectious Disease Biomarker Testing Market (by Region), 2019 and 2030
Figure 13.2: Global Infectious Disease Biomarker Testing Market (by Region), 2019-2030
Figure 13.3: North America: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: North America: Infectious Disease Biomarker Testing Market (by Country), 2019 and 2030
Figure 13.6: U.S.: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.7: Canada: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.8: Europe: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe: Infectious Disease Biomarker Testing Market (by Country), 2019 and 2030
Figure 13.11: Germany: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.12: U.K.: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.13: France: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.14: Italy: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.15: Spain: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.16: Switzerland: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.17: Netherlands: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.18: Rest-of-Europe: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.19: Asia-Pacific: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.20: Asia-Pacific: Market Dynamics
Figure 13.21: North America: Infectious Disease Biomarker Testing Market (by Country), 2019 and 2030
Figure 13.22: China: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.23: Japan: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.24: India: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.25: Australia: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.26: Singapore: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.27: Singapore: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.28: Rest-of-Asia-Pacific: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.29: Rest-of-the-World: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.30: Middle East and Africa: Market Dynamics
Figure 13.31: Rest-of-the-World: Infectious Disease Biomarker Testing Market (by Region), 2019 and 2030
Figure 13.32: Latin America: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 13.33: Middle East and Africa: Infectious Disease Biomarker Testing Market, 2019-2030
Figure 14.1: Shares of Key Company Profiles
Figure 14.2: Abacus Diagnostica Oy: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.3: Abacus Diagnostica Oy: SWOT Analysis
Figure 14.4: Abbott Laboratories: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.5: Abbott Laboratories: Overall Financials, 2017-2019
Figure 14.6: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 14.7: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 14.8: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 14.9: Abbott Laboratories: SWOT Analysis
Figure 14.10: Agilent Technologies, Inc.: Product Portfolio for the Global Infectious Disease Biomarker Testing Market
Figure 14.11: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.12: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 14.13: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.14: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.15: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.16: ALPCO: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.17: ALPCO: SWOT Analysis
Figure 14.18: Becton, Dickinson and Company: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.19: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 14.20: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
Figure 14.21: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019
Figure 14.22: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 14.23: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 14.24: Becton, Dickinson and Company: SWOT Analysis
Figure 14.25: bioMérieux SA: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.26: bioMérieux SA: Overall Financials, 2017-2019
Figure 14.27: bioMérieux SA: Revenue (by Segment), 2017-2019
Figure 14.28: bioMérieux SA: Revenue (by Region), 2017-2019
Figure 14.29: bioMérieux SA: R&D Expenditure, 2017-2019
Figure 14.30: bioMérieux SA: SWOT Analysis
Figure 14.31: Bio-Rad Laboratories, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.32: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 14.33: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 14.34: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 14.35: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 14.36: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.37: Danaher Corporation: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.38: Danaher Corporation: Overall Financials, 2017-2019
Figure 14.39: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 14.40: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 14.41: Danaher Corporation: R&D Expenditure (2017-2019)
Figure 14.42: Danaher Corporation: SWOT Analysis
Figure 14.43: F. Hoffmann-La Roche Ltd: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.44: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 14.45: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 14.46: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 14.47: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 14.48: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 14.49: Hologic, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.50: Hologic, Inc.: Overall Financials, 2017-2019
Figure 14.51: Hologic, Inc.: Revenue (by Segment), 2017-2019
Figure 14.52: Hologic, Inc.: Revenue (by Region), 2017-2019
Figure 14.53: Hologic, Inc.: R&D Expenditure, 2017-2019
Figure 14.54: Hologic, Inc.: SWOT Analysis
Figure 14.55: PerkinElmer, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.56: PerkinElmer, Inc.: Overall Financials, 2017-2019
Figure 14.57: PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
Figure 14.58: PerkinElmer, Inc.: Revenue (by Region), 2017-2019
Figure 14.59: PerkinElmer, Inc.: R&D Expenditure, 2017-2019
Figure 14.60: PerkinElmer, Inc.: SWOT Analysis
Figure 14.61: QIAGEN N.V.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.62: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 14.63: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 14.64: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 14.65: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 14.66: QIAGEN N.V.: SWOT Analysis
Figure 14.67: Quest Diagnostics Incorporated: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.68: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 14.69: Quest Diagnostics Incorporated.: Revenue (by Segment), 2017-2019
Figure 14.70: Quest Diagnostics Incorporated: SWOT Analysis
Figure 14.71: Siemens Healthineers AG: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.72: Siemens Healthineers AG: Overall Financials, 2017-2019
Figure 14.73: Siemens Healthineers AG: Revenue (by Segment), 2017-2019
Figure 14.74: Siemens Healthineers AG: Revenue (by Region), 2017-2019
Figure 14.75: Siemens Healthineers AG: R&D Expenditure, 2017-2019
Figure 14.76: Siemens Healthineers AG: SWOT Analysis
Figure 14.77: Thermo Fisher Scientific, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
Figure 14.78: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
Figure 14.79: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2017-2019
Figure 14.80: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2017-2019
Figure 14.81: Thermo Fisher Scientific, Inc.: R&D Expenditure (2017-2019)
Figure 14.82: Thermo Fisher Scientific, Inc.: SWOT Analysis
Report Description
|
Market Report Coverage - Infectious Disease Biomarker Testing |
|||
|
Base Year |
2019 |
Market Size in 2019 |
$5.64 Billion |
|
Forecast Period |
2020-2030 |
Value Projection and Estimation by 2030 |
$25.01 Billion |
|
CAGR During Forecast Period |
14.48% |
Number of Tables |
27 |
|
Number of Pages |
352 |
Number of Figures |
190 |
|
Research Hours |
700 |
|
|
|
Market Segmentation |
• By Product – Assays and Platforms • By Technology – PCR, NGS, ELISA or EIA, IHC, ISH, and Others • By Application – Respiratory Infection, Sexually Transmitted Infection, Bloodstream and Hospital Acquired Infection, Urinary Tract Infection, Gastro-Intestinal Infection, CNS Infection, and Others • By End User – Hospitals and Clinics, Diagnostic Centers, Academic Research Institutes, and Others • By Pathogen – Bacteria, Virus, Fungi, and Others |
||
|
Regional Segmentation |
• North America – U.S., Canada • Europe – Germany, U.K., France, Italy, Switzerland, Spain, Netherlands, and Rest-of-Europe • Asia-Pacific – China, Australia, Japan, India, South Korea, Singapore, and Rest-of-Asia-Pacific • Rest-of-the-World – Latin America and Middle East and Africa |
||
|
Growth Drivers |
• Increasing Burden of Pervasively Growing Rate of Infectious Diseases • Advancements in Molecular Techniques and Elevated Demand for Biomarker Tests in NGS • Boosting Research and Increasing Funding Activities for Clinical Biomarkers • Booming Clinical Diagnostic Test Market and Rising Uptake of Biomarker Tests Among Healthcare Professionals |
||
|
Market Challenges |
• Poorly Suited Reimbursement Policies • High Capital Investments and Lack of Intricate Testing Centres • Uncertain Regulatory Framework Delaying Tests Approval |
||
|
Market Opportunities |
• Untapped Potential of Emerging Nations Creating Vast Opportunities • Rapid Technological Advancements and Inclination Towards Automation • Widespread Emergence of CROs Specializing on Infectious Diseases |
||
|
Key Companies Profiled |
Abacus Diagnostica Oy, ALPCO, Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Hologic, Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. |
||
Key Questions Answered in this Report:
• What is a biomarker and what is the importance of biomarker testing?
• What are the different biomarker testing approaches for infectious diseases? What are utilities associated with clinical biomarkers and what are the different types of biomarker available for commercial application?
• What are the major advancements in infectious disease biomarker testing market? What are the key trends of the global infectious disease biomarker testing market? How is the market evolving and what is its future scope?
• What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
• What are the major drivers, challenges, and opportunities of the global infectious disease biomarker testing market?
• What is the impact of the novel corona virus outbreak on the global infectious disease biomarker testing market? How is COVID19 pandemic expected to influence the market in the upcoming years?
• What are the major key players of the global infectious disease biomarker testing market? How much market share does each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future and why?
• What are the key developmental strategies implemented by the key players of the global infectious disease biomarker testing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
• What was the market size of the global infectious disease biomarker testing market in 2019 and what is the market size anticipated to be in 2030? What is the expected growth rate of the global infectious disease biomarker testing market during the period between 2020 and 2030?
• What is the global market size of different types of products of the global infectious disease biomarker testing market in 2019? What are the key trends of the market with respect to different platforms and assays and which product is expected to dominate the market in 2030?
• What are the different technologies supported by the biomarker testing products? Which technology type dominated the market in 2019 and is expected to dominate in 2030?
• What are the different applications associated with infectious disease biomarker testing? What was the contribution of each of the application areas in the global infectious disease biomarker testing market for the time period between 2019 and 2030?
• How is the global infectious disease biomarker testing market segmented based on pathogen type? Which pathogen is currently leading the market and why? Which pathogen type is expected to lead the market during the forecast?
• What are the different end-users of the global infectious disease biomarker testing market? Which end-user type is the major contributor of revenue in the market?
• Which region is expected to contribute the highest sales in the global infectious disease biomarker testing market during the period between 2019 and 2030? What are the leading countries of different regions that contribute significantly toward the growth of the global infectious disease biomarker testing market?
Market Overview
Increasing prevalence of emerging and re-emerging infectious diseases continue to be instrumental in escalating the economic, social, and clinical burden across the globe. In 2016, the World Health Organization (WHO) placed three infectious diseases among the top ten causes of death. It included lower respiratory infections, diarrheal diseases, and tuberculosis, accounting for 3.0 million deaths, 1.4 million deaths, and 1.3 million deaths, respectively. Despite the immense effort across the world to control the occurrence of infectious diseases with the ever-evolving healthcare systems, the world continues to be confronted by infectious disease threats, most often in the form of epidemics, pandemics, or outbreaks. Thus, the soaring demand for better treatment outcome is leading to an ascending need for preventive, precise healthcare, and tailored medication. Diagnosis, being the first step to treatment, has always been an active area of investment owing to the increasing prevalence of infectious diseases. The field of diagnostics has undergone rapid transformation over the decades with the development and introduction of wide variety of products that aid in the diagnosis, screening, and prognosis of diseases. As a major segment of diagnostics, biomarker testing has evolved as one of the most transformative and dynamic areas of clinical diagnostics that continue to revolutionize healthcare across a broad continuum of infectious diseases. Owing to the recent COVID-19 outbreak, the global infectious disease biomarker testing market is expected to grow dynamically with a robust growth rate.
Our healthcare experts have found biomarker testing industry for infectious diseases to be one of the most rapidly evolving markets, and the global market for infectious disease biomarker testing market is predicted to grow at a CAGR of 14.48% during the forecast period of 2020-2030. This growth of the global infectious disease biomarker testing market is primarily attributed to the major drivers that include highly increasing global prevalence of infectious diseases, growth in the biomarker identification market and advancements in molecular techniques, rapid advances in biomarker testing platforms with improved speed, sensitivity, and patient compliance, and significant external funding for executing research and development exercises.
The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include a massive scope for adoption of infectious disease biomarker testing products in emerging nations, increase in the adoption of automation & multiplexing of technologies, and rise in number of CROs offering disease testing services. However, there are certain challenges that tends to restrain its growth. These challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers and complex regulatory frameworks delaying the approval of new tests. However, with increasing support from the government across all the countries of the world to uplift patient care and improve healthcare infrastructure, the infectious disease biomarker testing market is expected to grow vigorously. Entry of new companies in the market and launch of new biomarker testing product lines are further expected to boost its growth in the upcoming years.
Within the research report, the market is segmented on the basis of product, technology, pathogen, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the adoption of biomarker testing products for different application areas of infectious diseases on the global level has created a buzz among companies to invest significantly in global infectious disease biomarker testing market. The market is highly competitive, with the presence of various juggernauts such as F. Hoffmann-La Roche Ltd, Qiagen N.V., Siemens Healthineers AG, Beckman Coulter, Inc., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific Inc, and bioMérieux SA, among others. With the increasing demand for faster and accurate diagnostic measures, companies have the opportunity to expand their product portfolios in the market through different strategic approaches. Some of the common strategies followed by the contributors are partnership and alliances (collaborations and joint ventures), acquisitions, product offerings (launches), product approvals, and business expansion activities.
You may also like
Published Year:2020
Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, an
Global clinical biomarkers market analysis by BIS Research projects the market to grow at a...
Published Year:2018
Global Point of Care Testing Market - Analysis and Forecast (2017-2026): Focus on Application, Marke
The global POCT market was estimated at $13.87 billion in 2017 and is estimated to grow over...
Global Infectious Disease Biomarker Testing Market
Focus on Product Type, Technology, Pathogen, Application, End-user, 5 Regional Data, 15 Countries’ Data, and Competitive Landscape - Analysis and Forecast, 2020-2030